Target Price | $362.18 |
Price | $339.12 |
Potential |
6.80%
register free of charge
|
Number of Estimates | 11 |
11 Analysts have issued a price target United Therapeutics Corporation 2025 .
The average United Therapeutics Corporation target price is $362.18.
This is
6.80%
register free of charge
$575.00
69.56%
register free of charge
$243.00
28.34%
register free of charge
|
|
A rating was issued by 16 analysts: 8 Analysts recommend United Therapeutics Corporation to buy, 6 to hold and 2 to sell. | |
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
Analyst Estimates: Analysts believe that the United Therapeutics Corporation stock has an average upside potential 2025 of
6.80%
register free of charge
|
Dec '23 |
2024 Estimates |
|
---|---|---|
Revenue Billion $ | 2.33 | 2.84 |
20.20% | 21.89% | |
EBITDA Margin | 53.35% | 52.99% |
0.88% | 0.67% | |
Net Margin | 37.81% | 39.42% |
9.87% | 4.27% |
12 Analysts have issued a sales forecast United Therapeutics Corporation 2024 . The average United Therapeutics Corporation sales estimate is
This results in the following potential growth metrics:
6 Analysts have issued an United Therapeutics Corporation EBITDA forecast 2024. The average United Therapeutics Corporation EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
8 United Therapeutics Corporation Analysts have issued a net profit forecast 2024. The average United Therapeutics Corporation net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Dec '23 |
2024 Estimates |
|
---|---|---|
Earnings Per Share $ | 19.81 | 25.18 |
32.07% | 27.11% | |
P/E | 13.47 | |
EV/Sales | 4.45 |
8 Analysts have issued a United Therapeutics Corporation forecast for earnings per share. The average United Therapeutics Corporation <a href=https://blog.stocksguide.com/knowledge/eps-simply-explained>EPS is
This results in the following potential growth metrics and future valuations:
Based on analysts' sales estimates for 2024, the United Therapeutics Corporation stock is valued at an <a href=https://blog.stocksguide.com/knowledge/enterprise-value-sales-simply-explained>EV/Sales of
This results in the following potential growth metrics and future valuations:
United Therapeutics Corporation...
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.